1. What Is the Preclinical Imaging Market?
The Preclinical Imaging Market encompasses in vivo and in vitro imaging systems used in biomedical research to visualise biological processes, disease progression, and therapeutic responses in small animal models and laboratory specimens before clinical trials. The market includes micro-CT, MRI, PET, SPECT, bioluminescence, and fluorescence optical imaging platforms for small animal imaging, high-content screening microscopy platforms for cell-based assay imaging, and digital pathology scanners for histological specimen imaging. These systems are used by pharmaceutical and biotechnology researchers, academic basic science investigators, and contract research organisations to evaluate drug candidates, disease mechanisms, and biomarker validation in preclinical animal models and cell culture systems. Market scope covers preclinical imaging hardware platforms and associated imaging agents, software, and consumables for in vivo small animal and in vitro laboratory specimen imaging. It excludes clinical diagnostic imaging systems used in patient care and non-imaging life science analytical instruments.
2. Preclinical Imaging Market Size & Forecast
3. Emerging Technologies
- Artificial intelligence-driven automated image analysis for preclinical imaging is advancing convolutional neural network algorithms that automatically segment organs, tumours, and anatomical landmarks in micro-CT and MRI datasets, reducing post-acquisition image analysis time from hours. Growing industry adoption of this technology is motivating development.
- Multimodal registration software for simultaneous preclinical imaging is advancing image coregistration algorithms that align anatomical CT with functional optical or nuclear imaging data from the same animal acquired on separate systems, enabling combined. Growing.
- Germ-free small animal imaging systems are advancing contamination-controlled micro-CT and optical imaging chambers compatible with gnotobiotic animal transfer from germ-free housing, enabling preclinical imaging of gut microbiome studies and infectious disease models without conventional. Growing industry adoption of this technology is motivating development.
- Remote preclinical imaging facility access is advancing cloud-connected preclinical imaging systems that enable researchers at remote pharmaceutical sites to submit imaging study designs and receive processed imaging data from centralised. Growing pharmaceutical company interest.
Such innovations are driving change across adjacent industries too. Discover more in our In Vivo Optical Imaging Market.
4. Key Market Opportunity
One of the major opportunities in the Preclinical Imaging Market is the expansion of preclinical imaging adoption at pharmaceutical companies implementing imaging-based pharmacodynamic biomarker endpoints in early drug discovery to reduce late-stage clinical attrition from efficacy failure. A significant proportion of drug candidates that fail in phase II and III clinical trials demonstrate inadequate efficacy endpoints that could have been predicted earlier if quantitative pharmacodynamic imaging biomarker endpoints had been incorporated into the preclinical evaluation strategy. Preclinical imaging pharmacodynamic biomarker endpoints that quantify target engagement, pathway inhibition, and disease modification in animal models provide translatable mechanistic evidence that reduces the risk of clinical trial failure from efficacy uncertainty. Preclinical imaging system manufacturers that provide pharmacodynamic biomarker imaging application packages, quantitative image analysis toolkits, and translational biomarker evidence examples for key therapeutic areas are positioned to drive imaging adoption as a standard early drug discovery decision-making tool.
5. Top Companies in the Preclinical Imaging Market
The following organisations hold leading positions in the Preclinical Imaging Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Bruker
- PerkinElmer (IVIS)
- Siemens Healthineers (Preclinical)
- Fujifilm VisualSonics
- iThera Medical
- Rigaku
- MILabs
- Molecular Imaging Instruments
- Mediso
- Aspect Imaging
6. Market Segmentation
The Preclinical Imaging Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Modality | Micro-CT Small Animal CT Micro-CT System Optical Imaging Bioluminescence Imaging Fluorescence Imaging Nuclear Imaging Preclinical PET Preclinical SPECT Preclinical MRI Bore MRI System Photoacoustic Imaging Preclinical PAI High Content Imaging HCS System HCA Platform |
| By Application | Oncology Research Tumour Volume CT Tumour Optical BLI Neuroscience Brain MRI Small Animal CNS Drug PET Cardiovascular Cardiac Preclinical Imaging Infectious Disease Pathogen Optical Imaging Drug Discovery Efficacy Imaging Pharma Gene Therapy Vector Biodistribution Optical |
| By End User | Pharmaceutical Companies Drug Discovery Preclinical Biotechnology Companies Biotech Preclinical Research Academic Research Institutions University Research Imaging Contract Research Organisations Preclinical CRO Government Research NIH-Funded Research |
| By Geography | North America Europe Asia Pacific Latin America Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Preclinical Imaging Market trajectory over the forecast period:
Micro-CT Small Animal Imaging Technology Remains Essential for Three-Dimensional Bone, Tumour, and Organ Morphology Assessment in Preclinical Studies.Pharmaceutical and academic researchers performing drug efficacy and disease progression studies in mouse. Rat models are using micro-CT systems as the primary three-dimensional morphological assessment tool for bone density measurement in osteoporosis models, tumour volume measurement in oncology efficacy studies, and lung disease assessment in respiratory models. Bruker and Rigaku continued commercial development of SkyScan and CT Lab GX micro-CT systems for preclinical small animal imaging in 2024. This provides researchers with updated reconstruction algorithms and reduced scan time for in vivo rodent imaging applications.
Preclinical PET-CT Technology Is Enabling Quantitative Radiotracer Biodistribution and Drug Pharmacokinetics Assessment in Living Animal Models.Pharmaceutical researchers evaluating CNS drug candidate brain penetration, oncology drug tumour uptake, and immunotherapy target engagement are using preclinical PET-CT to measure radiotracer biodistribution in living animal models. This provides pharmacokinetic and pharmacodynamic data translatable to clinical FDG and novel radiotracer imaging. Siemens Healthineers and PerkinElmer continued commercial development of preclinical PET-CT systems in 2024, with growing pharmaceutical company preclinical imaging programme adoption of quantitative PET for CNS, oncology, and inflammation drug candidate evaluation.
Photoacoustic Imaging Technology Is Emerging as a Complementary Modality Providing Deep-Tissue Optical Contrast in Preclinical Animal Models.Biomedical researchers seeking non-ionising radiation alternatives to micro-CT for soft tissue contrast at depths beyond the penetration limit of fluorescence optical imaging are adopting photoacoustic imaging systems that convert pulsed laser energy to acoustic waves. This provides centimetre-depth tissue imaging with optical contrast resolution. iThera Medical and VisualSonics continued commercial development of photoacoustic imaging systems for preclinical vascular, tumour, and lymphatic vessel imaging in 2024. This grows academic and pharmaceutical research adoption of photoacoustic imaging for deep-tissue contrast beyond fluorescence optical imaging depth limitations.
For related market intelligence, see the Small Animal Imaging Market.
8. Segmental Analysis
By modality, micro-CT dominated the Preclinical Imaging Market in 2025, driven by the established role of small animal CT as the primary three-dimensional anatomical imaging modality for bone, tumour, and organ assessment across preclinical research. Pharmaceutical and academic researchers continue specifying micro-CT as the primary preclinical anatomical imaging system as three-dimensional CT datasets provide quantitative bone density, tumour volume, and organ morphology required for preclinical efficacy endpoints. Optical imaging systems are the fastest-growing modality, driven by growing bioluminescence and fluorescence imaging adoption for real-time in vivo cell tracking, reporter gene expression, and drug biodistribution assessment in transgenic and xenograft mouse models. Pharmaceutical researchers are increasing optical imaging adoption as bioluminescence reporter cell lines and fluorescent probe technologies expand the range of biological processes visible in living animal models with whole-body optical imaging sensitivity.
By application, oncology research dominated the Preclinical Imaging Market in 2025, driven by the high volume of cancer drug discovery programmes requiring tumour volume micro-CT, BLI reporter imaging, and PET metabolic activity in xenograft models. Pharmaceutical oncology researchers continue generating the highest preclinical imaging demand as tumour volume, drug distribution, and pathway engagement imaging endpoints are standard requirements in every preclinical oncology efficacy study design. Neuroscience is the fastest-growing application, driven by growing CNS drug candidate brain penetration and target engagement assessment demand using preclinical PET and MRI as Alzheimer's disease, Parkinson's disease, and psychiatric disorder programmes expand. Pharmaceutical neuroscience researchers are increasing preclinical PET and MRI adoption as CNS drug discovery programmes require quantitative brain pharmacokinetic and pharmacodynamic imaging biomarkers before advancing candidates to clinical development.
9. Regional Analysis
Regional demand patterns across the Preclinical Imaging Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Preclinical Imaging Market in 2025, with a market share of 44.0%. The region's leadership reflects the large United States pharmaceutical and biotechnology company preclinical research investment, the concentration of academic research institutions with NIH-funded preclinical imaging core facilities, and the headquarters of leading preclinical imaging instrument manufacturers with North American commercial operations. The large United States pharmaceutical and biotechnology sector generates consistent preclinical imaging system procurement as drug discovery and development programmes maintain dedicated in-house or CRO-accessed imaging platforms for efficacy, pharmacokinetics, and toxicology preclinical studies. The concentration of NIH-funded academic research centres maintaining shared preclinical imaging core facilities generates consistent preclinical imaging equipment replacement and expansion demand from competitive grant-funded biomedical research programmes.
Highest CAGR Region
Asia Pacific is expected to register the highest CAGR of 8.20% during the forecast period. Growing pharmaceutical and biotechnology research investment in China, Japan, South Korea, and India, expanding government biomedical research funding for preclinical imaging infrastructure, and increasing CRO sector preclinical imaging service capacity across the region are creating demand for preclinical imaging systems. Growing Chinese pharmaceutical company preclinical drug discovery investment is creating demand for preclinical imaging platforms at Chinese pharmaceutical research centres as drug discovery programmes require in vivo imaging for efficacy, pharmacokinetics, and disease model characterisation. Growing academic research infrastructure investment and increasing government biomedical science funding in South Korea, Japan, and Australia are creating consistent preclinical imaging system procurement at university research institutions and national biomedical research institutes.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Preclinical Imaging Market was valued at USD 3.82 Bn in 2025 and is projected to reach USD 6.40 Bn by 2034, growing at a CAGR of 5.90% over the 2026–2034 forecast period.
The Preclinical Imaging Market is projected to grow at a CAGR of 5.90% from 2026 to 2034.
North America dominated the Preclinical Imaging Market in 2025, with a market share of 44.0%.
The leading companies in the Preclinical Imaging Market include Bruker, PerkinElmer (IVIS), Siemens Healthineers (Preclinical), Fujifilm VisualSonics, iThera Medical, Rigaku, MILabs, Molecular Imaging Instruments, Mediso, Aspect Imaging.
Micro-ct small animal imaging technology remains essential for three-dimensional bone, tumour, and organ morphology assessment in preclinical studies.
By modality, micro-CT dominated the Preclinical Imaging Market in 2025, driven by the established role of small animal CT as the primary three-dimensional anatomical imaging modality for bone, tumour, and organ assessment across preclinical research.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.